Format

Send to

Choose Destination
See comment in PubMed Commons below
Biomed Res Int. 2014;2014:512831. doi: 10.1155/2014/512831. Epub 2014 Apr 2.

Human pluripotent stem cell-derived cardiomyocytes as research and therapeutic tools.

Author information

1
Department of Biology, Faculty of Medicine, Masaryk University, Kamenice 5/A3, 62500 Brno, Czech Republic.
2
Department of Biology, Faculty of Medicine, Masaryk University, Kamenice 5/A3, 62500 Brno, Czech Republic ; ICRC, St. Anne's University Hospital, 60200 Brno, Czech Republic.
3
INSERM U1046, University of Montpellier I, University of Montpellier II, 34295 Montpellier, France.
4
Department of Biology, Faculty of Medicine, Masaryk University, Kamenice 5/A3, 62500 Brno, Czech Republic ; INSERM U1046, University of Montpellier I, University of Montpellier II, 34295 Montpellier, France.

Abstract

Human pluripotent stem cells (hPSCs), namely, embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), with their ability of indefinite self-renewal and capability to differentiate into cell types derivatives of all three germ layers, represent a powerful research tool in developmental biology, for drug screening, disease modelling, and potentially cell replacement therapy. Efficient differentiation protocols that would result in the cell type of our interest are needed for maximal exploitation of these cells. In the present work, we aim at focusing on the protocols for differentiation of hPSCs into functional cardiomyocytes in vitro as well as achievements in the heart disease modelling and drug testing on the patient-specific iPSC-derived cardiomyocytes (iPSC-CMs).

PMID:
24800237
PMCID:
PMC3996932
DOI:
10.1155/2014/512831
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Support Center